Drugs / [177Lu]Lu-DPI-4452
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05706129 | Mar 2023 → Jun 2027 expected | clear cell renal carcinoma, colorectal carcinoma, head and neck cancer, infiltrating bladder urothelial carcinoma +3 | ITM Oncologics GmbH | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [177Lu]Lu-DPI-4452 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05706129 ↗ |
| Route | Intravenous | “administered as IV infusion.” NCT05706129 ↗ |